Mineralys Therapeutics (MLYS): SEC Form 3 filed by new insider Ferguson James J. Iii
Stocks in this Quantisnow insightHealth Care
Historical context for MLYS
Across the 26 sessions after earlier MLYS headlines, the stock closed higher 11 times and lower 15 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MLYS | SPY |
|---|---|---|---|
| Aug 12, 2026 | Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | -1.0% | +0.3% |
| Aug 4, 2026 | Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 | +2.8% | +1.8% |
| Jul 28, 2026 | Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | -1.0% | +0.2% |
| Jun 15, 2026 | Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) | +1.3% | +1.8% |
| Jun 9, 2026 | Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | +7.5% | -0.3% |
| Jun 3, 2026 | Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stockand 1 other headline that session | -13.1% | -0.7% |
Quantisnow market dataNASDAQ
MLYS
Mineralys Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2023
Get push alerts for MLYS
Full MLYS profile on Quantisnow Follow MLYS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time